RFK Jr. Vaccine Policy: First Steps
- vaccination policy is underway following Health Secretary Robert F.
- Kennedy's subsequent appointment of replacements, including figures known for questioning vaccine safety, has ignited controversy.
- Adding to the upheaval, Kennedy terminated over $1 billion in U.S.
Robert F. Kennedy Jr.’s recent moves have dramatically altered U.S. vaccination policy: Health Secretary Kennedy dismissed the entire CDC vaccine advisory panel, and over a billion dollars in funding for global vaccination efforts was cut. This drastic action, coupled with the appointment of individuals who question vaccine safety, is sparking intense debate. News Directory 3 reports on the new committee’s inaugural meeting, where significant concerns about vaccine safety and evidence-based medicine were raised. Learn how these shifts could impact vaccine confidence and public health initiatives. Discover what’s next …
Vaccine Panel Overhaul Sparks Debate on Science and Safety
Updated June 28, 2025
A dramatic shift in U.S. vaccination policy is underway following Health Secretary Robert F. Kennedy Jr.’s dismissal of all 17 voting members of the CDC’s Advisory Committee on Immunization Practices (ACIP) on June 9. The ACIP plays a crucial role in determining vaccine recommendations and coverage.
Kennedy’s subsequent appointment of replacements, including figures known for questioning vaccine safety, has ignited controversy. The new committee’s first meeting this week featured discussions that challenged established scientific consensus on vaccine safety.
Adding to the upheaval, Kennedy terminated over $1 billion in U.S. funding for Gavi, a global initiative supporting childhood vaccination programs. Lyn Redwood, formerly of the anti-vaccine organization Children’s Health Defense, has also been appointed as a special government employee.
During the ACIP meeting, members raised concerns about potential long-term effects of mRNA-based COVID vaccines and suggested a possible link between COVID-19 or its treatments and increased susceptibility to other illnesses. CDC staff addressed these concerns, citing existing safety data and behavioral shifts during the pandemic.
Retsef Levi, an MIT professor and former intelligence officer, questioned the data surrounding a new monoclonal antibody for preventing RSV in infants, despite prior reviews by the FDA and ACIP’s work group. Levi and Vicky Pebsworth, who is on the board of an anti-vaccine organization, ultimately voted against recommending the antibody.
The committee also discussed thimerosal, a vaccine ingredient that has been the subject of anti-vaccine activism. Cody Meissner,the only returning member of the committee,expressed concern that the discussion lacked scientific evidence.
Martin Kulldorff, the new ACIP chair, repeatedly emphasized the importance of “evidence-based medicine.” Though, some observers, like Laura Morris of the University of Missouri School of Medicine, felt that decisions were being driven by feelings and preferences rather than evidence.
What’s next
The changes to the ACIP and the shift in vaccination policy are expected to have far-reaching consequences for public health. The coming months will reveal the full impact of these decisions on vaccine confidence and disease prevention efforts.